Orchid inks deal with Sweden's Biovitrum

New Delhi, Oct 30 (UNI) Orchid Chemicals and Pharmaceuticals Ltd today announced that it has tied up with Sweden-based Biovitrum to undertake medicinal chemistry work to support certain drug discovery activities of Biovitrum AB (publ).

Biovitrum is an integrated biopharma company with a broad project portfolio and operations in drug discovery research, development, manufacturing and product sales.

The Chennai-based pharma-major considers this tie-up as another validation in its ability to offer world-class drug discovery services to reputed clients around the globe, an Orchid statement said.

With operations in Sweden and in the UK, Biovitrum conducts research and develops pharmaceuticals for for common diseases and conditions that affect smaller patient populations.

With 500 employees, it also develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries.

UNI CS SK DB1308